Correlation of fibrosis and transforming growth factor-beta type 2 levels in the eye.
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Approximately 1 out of every 10 eyes undergoing surgery for retinal detachment develops excessive intraocular fibrosis that can lead to traction retinal detachment and ultimate blindness. This disease process has been termed proliferative vitreoretinopathy (PVR). The ability to monitor and grade this fibrotic response accurately within the eye as well as the ability to aspirate vitreous cavity fluid bathing the fibrotic tissue makes this an ideal setting in which to investigate the development of fibrosis. Although laboratory studies have recently shown that transforming growth factor-beta (TGF-beta) can enhance fibrosis, little clinical evidence is yet available correlating the level of this or other growth factors with the degree of fibrosis in a clinical setting. We have found that vitreous aspirates from eyes with intraocular fibrosis associated with PVR have more than three times the amount of TGF-beta (1,200 +/- 300 pM [SEM]) found in eyes with uncomplicated retinal detachments without intraocular fibrosis (360 +/- 91 pM [SEM]). Using an in vitro assay, 84-100% of the TGF-beta activity could be blocked with specific antibodies against TGF-beta 2, whereas only 10-21% could be blocked by specific antibodies against TGF-beta 1. TGF-beta 1 was used in an animal model of traction retinal detachment. Since beta 1 and beta 2 have essentially identical biologic effects and only human beta 1 was available in quantities required, beta 1 was chosen for these in vivo studies. The injection of TGF-beta1 plus fibronectin (FN) but not TGF-beta1 alone into the vitreous cavity of rabbits resulted in the increased formation of intraocular fibrosis and traction retinal detachments as compared to control eyes. In previous studies, intravitreal FN levels were also found to be elevated in eyes with intraocular fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, S. (1957) · The American Statistician · doi:10.1080/00031305.1957.10501091 · Cited by 3,903
Roberts, A. B., Sporn, M. B., Assoian, R. K., Smith, J. M., Roche, N. S., Wakefield, L. M., Heine, U. I., Liotta, L. A., Falanga, V, & Kehrl, J. H. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.12.4167 · Cited by 2,866
Self-citationIgnotz, R. A., & Massagué, J. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)35666-1 · Cited by 2,492
Assoian, R. K., Komoriya, A., Meyers, C. A., Miller, D. M., & Sporn, M. B. (1983) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)32345-7 · Cited by 1,598
Self-citationKehrl, J. H., Wakefield, L. M., Roberts, A. B., Jakowlew, S., Alvarez-Mon, M., Derynck, R., Sporn, M. B., & Fauci, A. S. (1986) · The Journal of experimental medicine · doi:10.1084/jem.163.5.1037 · Cited by 1,582
Self-citationTransforming growth factor type beta induces monocyte chemotaxis and growth factor production.
Wahl, S. M., Hunt, D. A., Wakefield, L. M., McCartney-Francis, N., Wahl, L. M., Roberts, A. B., & Sporn, M. B. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.16.5788 · Cited by 1,272
Self-citationExpression and secretion of type beta transforming growth factor by activated human macrophages.
Assoian, R. K., Fleurdelys, B. E., Stevenson, H. C., Miller, P. J., Madtes, D. K., Raines, E. W., Ross, R., & Sporn, M. B. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.17.6020 · Cited by 970
Self-citationRoberts, A. B., Anzano, M. A., Lamb, L. C., Smith, J. M., & Sporn, M. B. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.9.5339 · Cited by 919
Self-citationGrowth Inhibitor from BSC-1 Cells Closely Related to Platelet Type β Transforming Growth Factor
Tucker, R. F., Shipley, G. D., Moses, H. L., & Holley, R. W. (1984) · Science · doi:10.1126/science.6093254 · Cited by 768
The transforming growth factor-β system, a complex pattern of cross-reactive ligands and receptors
Cheifetz, S., Weatherbee, J. A., Tsang, M. L.-S., Anderson, J. K., Mole, J. E., Lucas, R., & Massagué, J. (1987) · Cell · doi:10.1016/0092-8674(87)90192-9 · Cited by 706
Cited by
Transforming Growth Factor β in Tissue Fibrosis
Epstein, F. H., Border, W. A., & Noble, N. A. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411103311907 · Cited by 3,069
Shah, M., Foreman, D. M., & Ferguson, M. W. J. (1995) · Journal of Cell Science · doi:10.1242/jcs.108.3.985 · Cited by 1,169
TGF-β signaling in health, disease and therapeutics
Deng, Z., Fan, T., Xiao, C., Tian, H., Zheng, Y., Li, C., & He, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01764-w · Cited by 1,168
Transforming growth factor-beta in disease: the dark side of tissue repair.
Border, W. A., & Ruoslahti, E. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115821 · Cited by 1,105
Border, W. A., Noble, N. A., Yamamoto, T., Harper, J. R., Yamaguchi, Y., Pierschbacher, M. D., & Ruoslahti, E. (1992) · Nature · doi:10.1038/360361a0 · Cited by 974
The Transforming Growth Factor-βs
Roberts, A. B., & Sporn, M. B. (1991) · Peptide Growth Factors and Their Receptors I · doi:10.1007/978-1-4612-3210-0_8 · Cited by 861
Self-citationThe Transforming Growth Factor-βs
Roberts, A. B., & Sporn, M. B. (1990) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-49295-2_8 · Cited by 746
Self-citationKlaassen, I., Van Noorden, C. J. F., & Schlingemann, R. O. (2013) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2013.02.001 · Cited by 722
Flegr, J., Prandota, J., Sovičková, M., & Israili, Z. H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090203 · Cited by 700
Transforming Growth Factor‐β: Major Role in Regulation of Extracellular Matrix
ROBERTS, A. B., HEINE, U. I., FLANDERS, K. C., & SPORN, M. B. (1990) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1990.tb17931.x · Cited by 696
Self-citationPelton, R. W., Saxena, B., Jones, M., Moses, H. L., & Gold, L. I. (1991) · The Journal of cell biology · doi:10.1083/jcb.115.4.1091 · Cited by 670
Transforming growth factor βs and wound healing
O'Kane, S., & Ferguson, M. W. J. (1997) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(96)00120-3 · Cited by 634
The cell biology of transforming growth factor β
Barnard, J. (1990) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(90)90013-q · Cited by 524
Khalil, N., O'Connor, R. N., Unruh, H. W., Warren, P. W., Flanders, K. C., Kemp, A., Bereznay, O. H., & Greenberg, A. H. (1991) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/ajrcmb/5.2.155 · Cited by 521
Neutralising antibody to TGF-β1,2 reduces cutaneous scarring in adult rodents
Shah, M., Foreman, D. M., & Ferguson, M. W. J. (1994) · Journal of Cell Science · doi:10.1242/jcs.107.5.1137 · Cited by 498
TGF-β: Regulation of extracellular matrix
Roberts, A. B., McCune, B. K., & Sporn, M. B. (1992) · Kidney International · doi:10.1038/ki.1992.81 · Cited by 493
Self-citationDignass, A. U., & Podolsky, D. K. (1993) · Gastroenterology · doi:10.1016/0016-5085(93)90136-z · Cited by 446
Transforming growth factor beta (TGF-?) in inflammation: A cause and a cure
Wahl, S. M. (1992) · Journal of Clinical Immunology · doi:10.1007/bf00918135 · Cited by 407
Antifibrotics and Wound Healing in Glaucoma Surgery
Lama, P. J., & Fechtner, R. D. (2003) · Survey of Ophthalmology · doi:10.1016/s0039-6257(03)00038-9 · Cited by 389
Myofibroblast transdifferentiation: The dark force in ocular wound healing and fibrosis
Shu, D. Y., & Lovicu, F. J. (2017) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2017.08.001 · Cited by 387
Malecaze, F. (1994) · Archives of Ophthalmology · doi:10.1001/archopht.1994.01090230090028 · Cited by 364
ROBERTS, A., TIAN, F., BYFIELD, S., STUELTEN, C., OOSHIMA, A., SAIKA, S., & FLANDERS, K. (2006) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.09.008 · Cited by 348
Self-citationTransforming growth factor-β in human aqueous humor
Jampel, H. D., Roche, N., Stark, W. J., & Roberts, A. B. (1990) · Current Eye Research · doi:10.3109/02713689009069932 · Cited by 347
Self-citationTGFβ2-Induced Changes in Human Trabecular Meshwork: Implications for Intraocular Pressure
Fleenor, D. L., Shepard, A. R., Hellberg, P. E., Jacobson, N., Pang, I.-H., & Clark, A. F. (2006) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.05-1060 · Cited by 322
EMT and EndMT: Emerging Roles in Age-Related Macular Degeneration
Shu, D. Y., Butcher, E., & Saint-Geniez, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124271 · Cited by 292
Proliferative Vitreoretinopathy: A Review
Idrees, S., Sridhar, J., & Kuriyan, A. E. (2019) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000258 · Cited by 291
Smad3 Signaling Is Required for Epithelial-Mesenchymal Transition of Lens Epithelium after Injury
Saika, S., Kono-Saika, S., Ohnishi, Y., Sato, M., Muragaki, Y., Ooshima, A., Flanders, K. C., Yoo, J., Anzano, M., Liu, C.-Y., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63153-7 · Cited by 283
Self-citationSaika, S. (2006) · Laboratory Investigation · doi:10.1038/labinvest.3700375 · Cited by 270
Transforming growth factor-β2 levels in aqueous humor of glaucomatous eyes
Inatani, M., Tanihara, H., Katsuta, H., Honjo, M., Kido, N., & Honda, Y. (2001) · Graefe's Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s004170000241 · Cited by 270
Lorenz, H. P. (2003) · Frontiers in Bioscience · doi:10.2741/1183 · Cited by 268
Transforming Growth Factor-β2 for the Treatment of Full-thickness Macular Holes
Glaser, B. M., Michels, R. G., Kuppermann, B. D., Sjaarda, R. N., & Pena, R. A. (1992) · Ophthalmology · doi:10.1016/s0161-6420(92)31837-8 · Cited by 265
Self-citationTherapeutic strategies against TGF‐β signaling pathway in hepatic fibrosis
Liu, X., Hu, H., & Yin, J. Q. (2006) · Liver International · doi:10.1111/j.1478-3231.2005.01192.x · Cited by 261
Rapid onset synovial inflammation and hyperplasia induced by transforming growth factor beta.
Allen, J. B., Manthey, C. L., Hand, A. R., Ohura, K., Ellingsworth, L., & Wahl, S. M. (1990) · The Journal of experimental medicine · doi:10.1084/jem.171.1.231 · Cited by 258
El-Sakka, A. I., Hassoba, H. M., Pillarisetty, R. J., Dahiya, R., & Lue, T. F. (1997) · Journal of Urology · doi:10.1016/s0022-5347(01)64223-x · Cited by 250
Cytokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy
Elner, S. G., Elner, V. M., Jaffe, G. J., Stuart, A., Kunkel, S. L., & Strieter, R. M. (1995) · Current Eye Research · doi:10.3109/02713689508998529 · Cited by 228
Wiedemann, P. (1992) · Survey of Ophthalmology · doi:10.1016/0039-6257(92)90115-a · Cited by 199
Role of Epithelial-Mesenchymal Transition in Retinal Pigment Epithelium Dysfunction
Zhou, M., Geathers, J. S., Grillo, S. L., Weber, S. R., Wang, W., Zhao, Y., & Sundstrom, J. M. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00501 · Cited by 196
“Previous studies have shown that the amount of TGF-β in the vitreous from eyes with PVR is three times higher than that of eyes without intraocular fibrosis (Connor et al., 1989; Kita et al., 2008).”
BackgroundTGF-β-induced fibrosis: A review on the underlying mechanism and potential therapeutic strategies
Ong, C. H., Tham, C. L., Harith, H. H., Firdaus, N., & Israf, D. A. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174510 · Cited by 183
Fibrotic disorders in the eye: Targets of gene therapy
Saika, S., Yamanaka, O., Sumioka, T., Miyamoto, T., Miyazaki, K.-I., Okada, Y., Kitano, A., Shirai, K., Tanaka, S.-I., & Ikeda, K. (2008) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2007.12.002 · Cited by 173
Granulomatous reaction to Bruch's membrane in age-related macular degeneration
Dastgheib, K. (1994) · Archives of Ophthalmology · doi:10.1001/archopht.1994.01090180111045 · Cited by 162
Takahashi, E., Nagano, O., Ishimoto, T., Yae, T., Suzuki, Y., Shinoda, T., Nakamura, S., Niwa, S., Ikeda, S., Koga, H., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.056523 · Cited by 162
Role of epithelial–mesenchymal transition in proliferative vitreoretinopathy
Tamiya, S., & Kaplan, H. J. (2016) · Experimental Eye Research · doi:10.1016/j.exer.2015.02.008 · Cited by 160
Is neutralizing vitreal growth factors a viable strategy to prevent proliferative vitreoretinopathy?
Pennock, S., Haddock, L. J., Eliott, D., Mukai, S., & Kazlauskas, A. (2014) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2013.12.006 · Cited by 158
“For instance, the vitreal level of TGFb family members (primarily TGFb2) increases as patients or experimental animals develop PVR (Asaria et al., 2004; Baudouin et al., 1993; Connor et al., 1989; Kita et al., 2008, 2007a; Pennock et al., 2011).”
p38 Inhibitors Prevent TGF-β–Induced Myofibroblast Transdifferentiation in Human Tenon Fibroblasts
Meyer-ter-Vehn, T., Gebhardt, S., Sebald, W., Buttmann, M., Grehn, F., Schlunck, G., & Knaus, P. (2006) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.05-0361 · Cited by 125
“All three TGF- isoforms have been identified in the eye,(18,19) with TGF- 2 the predominant isoform associated with ocular scarring diseases such as proliferative vitreoretinopathy and posterior lens capsule opacification.(20,21) TGF- signaling is mediated by binding of TGF- to its heteromeric receptor complex, consis…”
BackgroundGrowth factor and procollagen type I gene expression in human liver disease
Malizia, G., Brunt, E. M., Peters, M. G., Rizzo, A., Broekelmann, T. J., & McDonald, J. A. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90019-5 · Cited by 89
Kuiper, E. J. (2006) · Archives of Ophthalmology · doi:10.1001/archopht.124.10.1457 · Cited by 89
“Transforming growth factor is a major growth factor known to cause fibrosis and scarring processes in the skin and other organs, including the eye.(39-41) It uses CTGF as its main downstream mediator to induce fibrosis.”
BackgroundZhang, C., Miyagishima, K. J., Dong, L., Rising, A., Nimmagadda, M., Liang, G., Sharma, R., Dejene, R., Wang, Y., Abu-Asab, M., et al. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz171 · Cited by 26
“Consistent with these reports, TGF-β-2 is overexpressed in the RPE of AMD donor eyes afflicted with choroidal neovascularization/macular degeneration and in the vitreous aspirates of patients with proliferative vitreoretinopathy (40,41).”
Result
Metadata
- Authors
- Connor, T. B., Roberts, A. B., Sporn, M. B., Danielpour, D., Dart, L. L., Michels, R. G., de Bustros, S., Enger, C., Kato, H., & Lansing, M.
- Venue
- Journal of Clinical Investigation
- Published
- 1989-05-01
- Volume
- 83
- Issue
- 5
- Pages
- 1661-1666
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2071787763
- Cited by
- 481
- References
- 28
- FWCI
- 17.35
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.